Effects of mammalian target of rapamycin inhibitors on fibrosis after trabeculectomy

• Published in: Experimental eye research 2021-02, Vol.203, p.108421-108421, Article 108421
• Main Authors: Igarashi, Nozomi, Honjo, Megumi, Aihara, Makoto
• Format: Article
• Language: English
• Subjects: Actins - genetics; Actins - metabolism; Animals; Blotting, Western; Cells, Cultured; Collagen Type I - genetics; Collagen Type I - metabolism; Conjunctiva - metabolism; Conjunctiva - pathology; Fibroblasts - metabolism; Fibroblasts - pathology; Fibronectins - genetics; Fibronectins - metabolism; Fibrosis; Human conjunctival fibroblasts; Humans; Immunohistochemistry; Male; mTOR; Naphthyridines - pharmacology; Rabbits; Rapamycin; Real-Time Polymerase Chain Reaction; RNA, Messenger - genetics; Sirolimus - pharmacology; TOR Serine-Threonine Kinases - antagonists & inhibitors; Torin 1; Trabeculectomy; Transforming Growth Factor beta1 - pharmacology
• ISSN: 0014-4835; 1096-0007
• DOI: 10.1016/j.exer.2020.108421

Glaucoma, the second leading cause of blindness worldwide, is characterized by aberrant elevations of intraocular pressure (IOP), which can damage the optic nerve. IOP reduction is the only effective therapy for prevention of visual impairment and blindness in both hypertensive and normotensive individuals, and in some cases, trabeculectomy is a major surgical procedure that can lower IOP in patients with glaucoma. No matter how surgical technique and postoperative care advances, excessive scarring and tissue fibrosis could result from increased human conjunctival fibroblast (HCF) proliferation and extracellular matrix (ECM) deposition of the subconjunctival tissue and scleral flaps would persist after trabeculectomy. And these issues are major impediments to IOP reduction and filtering of bleb formations, so the modulation of the factors which can induce fibrosis could used as a novel strategy to control scarring after trabeculectomy. In this study, we examined the effects of mammalian target of rapamycin (mTOR) inhibitors (rapamycin or Torin1) on the fibrotic response induced by transforming growth factor-beta 1 (TGF-β1) in cultured human conjunctival fibroblast (HCF) cells. The study also examined the effects of mTOR inhibitor on fibrosis after trabeculectomy in rabbit eyes. In in vitro studies, we stimulated HCFs with TGF-β1, and confirmed that the expression levels of fibronectin, collagen type I alpha 1 chain (COL1A1), and α-smooth muscle actin (SMA) were significantly upregulated in HCFs with TGF-β1, by means of quantitative real-time polymerase chain reaction and immunocytochemistry. And those TGF-β1-induced changes were significantly attenuated with mTOR inhibitors, rapamycin or Torin1. Additionally the migration rate of HCFs was examined under conditions of TGF-β1 induction, TGF-β1-induced changes were significantly attenuated with mTOR inhibitors. A rabbit model of trabeculectomy was examined in vivo, and the effects of topical mTOR inhibitor were also examined, and found that topical treatment with mTOR inhibitor significantly suppressed collagen deposition in rabbit eyes after trabeculectomy. These results have demonstrated that mTOR inhibitors may provide a novel treatment modality for reducing the fibrotic response in HCFs and improving bleb scarring after filtration surgery. •Fibrosis induced with TGF-β1 in HCFs were suppressed by mTOR inhibitors.•mTOR inhibitor suppressed collagen deposition in rabbit eyes after trabeculectomy.•mTOR inhibi